Compare BGC & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGC | ALKS |
|---|---|---|
| Founded | 1945 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.8B |
| IPO Year | 1999 | 1991 |
| Metric | BGC | ALKS |
|---|---|---|
| Price | $8.78 | $29.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $14.50 | ★ $42.85 |
| AVG Volume (30 Days) | ★ 2.7M | 2.5M |
| Earning Date | 11-06-2025 | 10-28-2025 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | ★ 36.46 | 2.44 |
| EPS | 0.33 | ★ 2.02 |
| Revenue | ★ $2,640,884,000.00 | $1,521,338,000.00 |
| Revenue This Year | $36.34 | N/A |
| Revenue Next Year | $11.45 | $24.22 |
| P/E Ratio | $26.63 | ★ $14.67 |
| Revenue Growth | ★ 24.59 | 1.08 |
| 52 Week Low | $7.24 | $25.17 |
| 52 Week High | $10.96 | $36.45 |
| Indicator | BGC | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 47.99 | 48.29 |
| Support Level | $8.52 | $28.96 |
| Resistance Level | $8.76 | $30.10 |
| Average True Range (ATR) | 0.21 | 0.92 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 72.79 | 68.21 |
BGC Group Inc is a brokerage and financial technology company that serves financial markets, energy, and commodities markets. Its service and product offerings include brokerage for a wide range of financial products, including fixed income, equities, commodities, derivatives, and real estate, software solutions for trading platforms, clearing, trade execution, and other back-office services. Its clients mostly include banks, financial institutions, and corporate clients. BGC operates in one reportable segment, which is providing brokerage services. Geographically, the company generates a majority of its revenue from Europe, Middle East and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.